A Study of Pegasys Monotherapy in Patients With Chronic Hepatitis B Who Have Participated in Previous Studies
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | September 2009 |
| End Date: | March 2013 |
In this open-label multicenter study the long-term effect of Pegasys monotherapy on
pharmacodynamic HBV-related markers will be investigated in patients with chronic hepatitis
B. Eligible patients will have completed treatment on another donor protocol (e.g. PP22512)
and will receive Pegasys at an appropriate dose based on the standard of care (180mcg sc
once weekly) for up to 48 weeks. Target sample size is <100.
We found this trial at
1
site
Click here to add this to my saved trials
